Sangamo Biosciences, Inc.
105 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
Recorded as renamed to Sangamo Therapeutics, Inc. (2017)
3
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 25, 2027The maintenance fee for Rapid Screening of Biologically Active Nucleases and Isolation of Nuclease-Modified Cells (US 9,115,409) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 1 fee due Mar 1, 2027The maintenance fee for Rapid Screening of Biologically Active Nucleases and Isolation of Nuclease-Modified Cells (US 9,121,072) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Methods and Compositions for Gene Correction (US 9,267,123) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
Recent changes
- 6 terms have ended since Aug 23, 2026
- Oct 30 US 10,113,207 Methods and Compositions for Targeted Single-Stranded Cleavage and Targeted Integration · lapsed on the fee record
- Sep 23 US 8,841,260 Methods and Compositions for Treating Huntington's Disease · lapsed on the fee record
- Sep 11 US 10,072,066 Methods and Compositions for Treatment of a Beta Thalessemia · lapsed on the fee record
- Sep 11 US 10,072,062 Methods and Compositions for Modification of a Hla Locus · lapsed on the fee record
- Sep 2 US 8,822,221 Targeted Integration into the PPP1R12C Locus · lapsed on the fee record
- Aug 23 US 7,795,209 Anti-Angiogenic Methods and Compositions · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,947,873 | Compositions and methods for regulation of plant gamma-tocopherol methyltransferase In force · USPTO record | In force | USPTO record | |
| US 9,115,409 | Rapid Screening of Biologically Active Nucleases and Isolation of Nuclease-Modified Cells In force · High confidence | In force | High confidence | |
| US 9,121,072 | Rapid Screening of Biologically Active Nucleases and Isolation of Nuclease-Modified Cells In force · High confidence | In force | High confidence | |
| US 9,629,930 | Methods and Compositions for Treating Hemophilia B In force · High confidence | In force | High confidence | |
| US 9,631,187 | Methods and Compositions for Gene Correction In force · High confidence | In force | High confidence | |
| US 9,567,573 | Genome editing of a Rosa locus using nucleases In force · High confidence | In force | High confidence | |
| US 9,267,123 | Methods and Compositions for Gene Correction In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 105 patents in force now held by others · 73 lapsed for an unpaid fee · 72 ended at full term · 2 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
26 abandoned · 24 no status recorded